[BOOK][B] BPMN method and style
B Silver, B Richard - 2009 - ebpm.ir
The unique approach of the first edition, including segregation of the palette into “levels,” a
prescriptive modeling methodology, and principles of BPMN “style”, have all been carried vi| …
prescriptive modeling methodology, and principles of BPMN “style”, have all been carried vi| …
[HTML][HTML] Safety and efficacy of mitapivat in pyruvate kinase deficiency
…, AJ Barbier, S Bodie, B Silver… - … England Journal of …, 2019 - Mass Medical Soc
Background Pyruvate kinase deficiency is caused by mutations in PKLR and leads to
congenital hemolytic anemia. Mitapivat is an oral, small-molecule allosteric activator of pyruvate …
congenital hemolytic anemia. Mitapivat is an oral, small-molecule allosteric activator of pyruvate …
Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin
…, J Gokemeijer, L Iacono, C Eaton, BA Silver… - Clinical Cancer …, 2011 - AACR
Purpose: To determine the maximum tolerated dose (MTD), safety, pharmacokinetics,
pharmacodynamics, immunogenicity, and preliminary antitumor activity of CT-322 (BMS-844203), …
pharmacodynamics, immunogenicity, and preliminary antitumor activity of CT-322 (BMS-844203), …
Phase 1 single‐and multiple‐ascending‐dose randomized studies of the safety, pharmacokinetics, and pharmacodynamics of AG‐348, a first‐in‐class allosteric …
…, L Silverman, M Goldwasser, BA Silver… - Clinical …, 2019 - Wiley Online Library
Pyruvate kinase deficiency is a chronic hemolytic anemia caused by mutations in PK‐R, a
key glycolytic enzyme in erythrocytes. These 2 phase 1 randomized, placebo‐controlled, …
key glycolytic enzyme in erythrocytes. These 2 phase 1 randomized, placebo‐controlled, …
Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma
…, J Drappatz, T Coyle, L Fichtel, B Silver… - Investigational new …, 2015 - Springer
VEGF signaling through VEGFR-2 is the major factor in glioblastoma angiogenesis. CT-322,
a pegylated protein engineered from the 10th type III human fibronectin domain, binds the …
a pegylated protein engineered from the 10th type III human fibronectin domain, binds the …
Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL).
…, S Ma, SM O'Brien, E Evans, H Lounsbury, BA Silver… - 2012 - ascopubs.org
8032 Background: Btk supports activation, survival, and proliferation of malignant B cells in
CLL and B-NHL. AVL-292 is an oral, potent (IC 50 < 0.5nM), selective small molecule …
CLL and B-NHL. AVL-292 is an oral, potent (IC 50 < 0.5nM), selective small molecule …
Disinfection of N95 respirators with ozone
…, MD Stephens, S Patel, S Dufresne, B Silver… - MedRxiv, 2020 - medrxiv.org
The coronavirus disease 2019 crisis is creating a shortage of personal protective equipment
(PPE), most critically, N95 respirators for healthcare personnel. Our group was interested in …
(PPE), most critically, N95 respirators for healthcare personnel. Our group was interested in …
Cimetidine potentiation of the hypoprothrombinemic effect of warfarin
BA SILVER, WR BELL - Annals of Internal Medicine, 1979 - acpjournals.org
Excerpt Oral anticoagulants of the coumarin class are subject to both potentiating and inhibitory
drug interactions, some of which are clinically significant (1, 2). We report the case of a …
drug interactions, some of which are clinically significant (1, 2). We report the case of a …
Visualization of ingested medications in the stomach by ultrasound
Y Amital, B Silver, JB Leikin, H Frischer - The American journal of …, 1992 - Elsevier
The authors describe a potential application of ultrasound in detection of pills in the stomach,
and report the first case of its use in a patient. Thirty pills were studied in vitro by ultrasound…
and report the first case of its use in a patient. Thirty pills were studied in vitro by ultrasound…
[HTML][HTML] Phase I single (SAD) and multiple ascending dose (MAD) studies of the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AG-348, a …
…, C Hill, H Kim, P Kosinski, C Kung, B Silver… - Blood, 2014 - Elsevier
INTRODUCTION: Pyruvate kinase deficiency (PKD) is an inborn error of metabolism affecting
children and adults that results in lifelong hemolytic anemia and is associated with serious …
children and adults that results in lifelong hemolytic anemia and is associated with serious …
